Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Mulder, FI; Kraaijpoel, N; Di Nisio, M; Meyer, G; Mahe, I; Munoz, A; Bertoletti, L; Biosca, M; Maraveyas, A; Buller, HR; van Es, N.

The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism

THROMBOSIS RESEARCH. 2019; 181: 59-63 Nº de citas: 9 [doi:10.1016/j.thromres.2019.07.005]

Riechelmann, RP; Srimuninnimit, V; Bordonaro, R; Kavan, P; Di Bartolomeo, M; Maiello, E; Cicin, I; Garcia-Alfonso, P; Chau, I; Fedyanin, MY; Martos, CF; Ter-Ovanesov, M; Peeters, M; Ko, YJ; Yalcin, S; Karthaus, M; Aparicio, J; Heinemann, V; Picard, P; Bury, D; Drea, E; Sobrero, A.

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

CLINICAL COLORECTAL CANCER. 2019; 18(3): 183 Nº de citas: 16 [doi:10.1016/j.clcc.2019.05.003]

Mancha, RG; Munoz, M; de la Cruz-Merino, L; Calvo, L; Cruz, J; Baena-Canada, JM; Fernandez, Y; Ramos, M; Rodriguez, CA; Chacon, JI; Palomero, I; Llinares, J; Rivero, M; Ruiz, MA.

Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q"

HEALTH AND QUALITY OF LIFE OUTCOMES. 2019; 17(1): Nº de citas: 6 [doi:10.1186/s12955-019-1197-7]

Trigo, J; Vermorken, J; Bourhis, J; Psyrri, A; Nangia, CS; Chaves-Conde, M; Del Campo, JM; Wang, BS; Gibson, N; Ehrnrooth, E; Cohen, EEW; Giglio, RE; Blajman, CR; Freue, JM; Pilnik, NG; Palazzo, FS; McGrath, M; Fureder, T; Kornek, G; Pichler, A; Bauernhofer, T; Tinchon, C; Greil, R; Burian, M; Kienzer, H; Specenier, P; Sautois, B; Debruyne, P; Graas, MP; Maes, A; Lonchay, C; Daisne, JF; Fontaine, C; Castro, G; de Oliveira, F; Pereira, RP; De Marchi, PRM; Viana, LD; Segalla, JGM; Nicolau, UR; Lazaretti, NS; Kulkarni, S; Alam, Y; Ho, C; Shenouda, G; Soulieres, D; Sultanem, K; Singh, S; Mella, PG; Campos, JAS; Holeckova, P; Prausova, J; Obermannova, R; Friborg, J; Specht, L; Elsaid, AA; Minn, H; Martin, L; Rolland, F; Ceruse, P; Calais, G; Even, C; Guigay, J; Ferte, C; Peyrade, F; Duffaud, F; Champeaux-Orange, E; Coutte, A; Clatot, F; Fournel, P; Le Moal, LB; Dietz, A; Grunwald, V; Gauler, T; Guntinas-Lichius, O; Hildebrandt, G; Kuhnt, T; Schmidt, HJ; Henke, M; Ruckert, A; Brugger, W; Rotter, N; Mahlberg, R; Karavasilis, V; Fountzilas, G; Psyrri, D; Lang, I; Boer, A; Kocsis, J; Pajkos, G; Tamas, L; Anand, AL; Sharma, A; Sharma; Voona, M; Pandy, AS; Kumar, K; Nathan, RKP; Srinivasan, V; Zade, B; Jain, M; Srinivasa, BJ; Naik, R; Mohanty, BK; Asarawala, N; Charas, T; Billan, S; Popovtzer, A; Licitra, L; Ferrari, D; Fao, P; Merlano, M; Rocca, MC; Homma, A; Fujii, H; Tahara, M; Minami, S; Fujii, M; Yokota, T; Kadowaki, S; Muro, K; Kiyota, N; Okami, K; Yagi, T; Yoshino, K; Matsumoto, K; Takahashi, S; Matsuura, K; Avitia, MAA; Riestra, HJG; van Meerten, E; Buter, J; Gelderblom, AJ; Kawecki, A; Golusinski, W; Dinis, J; Dinis, R; Ribeiro, L; Silva, R; Mansinho, H; Selezneva, I; Biakhov, M; Galiulin, R; Izmailov, A; Romanov, I; Vladimirov, V; Vinogradov, V; Mufazalov, F; Vasilevskaya, I; Baste, N; del Campo, JM; Nin, RM; Pousa, AL; de Castro, JJG; Reig, O; Vera, R; Trigo, J; Iglesias, L; Trufero, JM; Vazquez, S; Rubio, B; Ales, JE; Villar, E; Rubio, J; Escobar, Y; Soria, A; Chaves, M; Johansson, GW; Friesland, S; Tell, R; Nyman, J; Rothschild, S; Zippelius, A; Rauch, D; Usluoglu, N; Gogunska, I; Zabolotniy, D; Vinnyk, Y; Burian, O; Harrington, K; Sykes, A; Peel, D; Lester, J; Robinson, M; Srinivasan, D; Fragkandrea-Nixon, I; Junor, E; Gollins, S; Evans, M; Newbold, K; Hwang, D; Schipani, S; Rizwanullah, M; Atiq, O; Arnaoutakis, K; Bauman, J; Burtness, B; Mehra, R; Kang, H; Chung, C; Davis, T; Haddad, R; Jimeno, A; Keresztes, R; Nangia, C; Ignatius, SH; Su, YB; Overton, LC; Garrison, MA; Jeong, W; Wehbe, A; Argiris, A; Chiang, A; Morgensztern, D; Haigentz, M; Martincic, D; Porosnicu, M; LUX-HEAD & Neck 2 Investigators.

Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial

JAMA Oncology. 2019; 5(8): 1170-1180 Nº de citas: 20 [doi:10.1001/jamaoncol.2019.1146]

Martin, M; Loibl, S; Hyslop, T; De la Haba-Rodriguez, J; Aktas, B; Cirrincione, CT; Mehta, K; Barry, WT; Morales, S; Carey, LA; Garcia-Saenz, JA; Partridge, A; Martinez-Janez, N; Hahn, O; Winer, E; Guerrero-Zotano, A; Hudis, C; Casas, M; Rodriguez-Martin, C; Furlanetto, J; Carrasco, E; Dickler, MN; GEICAM Spanish Breast Canc Grp; GBG; Alliance Clinical Trials Oncolog.

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials

EUROPEAN JOURNAL OF CANCER. 2019; 117: 91-98 Nº de citas: 16 [doi:10.1016/j.ejca.2019.06.002]

Ruiz-Borrego, M; Guerrero-Zotano, A; Bermejo, B; Ramos, M; Cruz, J; Baena-Canada, JM; Cirauqui, B; Rodriguez-Lescure, A; Alba, E; Martinez-Janez, N; Munoz, M; Antolin, S; Alvarez, I; Del Barco, S; Sevillano, E; Chacon, JI; Anton, A; Escudero, MJ; Ruiz, V; Carrasco, E; Martin, M; Segui, MA; Ayala, F; de la Haba, J; Martinez, P; Gonzalez, S; Lahuerta, A; Toral, JC; de Duenas, EM; Florian, J; Godes, MJ; Llorca, C; Blancas, I; Jara, C; Morales, S; Arcusa, A; Martinez, A; Vicente, E; de Juan, A; Rodriguez, M; Garcia, M; Garcia, P; Bayo, JL; Caranana, V; Casinello, J; Jolis, L; Gil, M; Canabate, C; Oltra, A; Ramirez, J; Lomas, M; Barnadas, A; Sureda, M; Carabantes, F; Moreno, I; Moreno, AL; GEICAM.

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study

BREAST CANCER RESEARCH AND TREATMENT. 2019; 177(1): 115-125 Nº de citas: 17 [doi:10.1007/s10549-019-05296-8]

Peters, S; Clezardin, P; Marquez-Rodas, I; Niepel, D; Gedyes, C.

The RANK-RANKL axis: an opportunity for drug repurposing in cancer?

CLINICAL & TRANSLATIONAL ONCOLOGY. 2019; 21(8): 977-991 Nº de citas: 25 [doi:10.1007/s12094-018-02023-5]

Calles, A; Aguado, G; Sandoval, C; Alvarez, R.

The role of immunotherapy in small cell lung cancer

CLINICAL & TRANSLATIONAL ONCOLOGY. 2019; 21(8): 961-976 Nº de citas: 93 [doi:10.1007/s12094-018-02011-9]

Kraaijpoel N; Bleker SM; Meyer G; Mahé I; Muñoz A; Bertoletti L; Bartels-Rutten A; Beyer-Westendorf J; Porreca E; Boulon C; van Es N; Iosub DI; Couturaud F; Biosca M; Lerede T; Lacroix P; Maraveyas A; Aggarwal A; Girard P; Büller HR; Di Nisio M; UPE investigators.

Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study.

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(20): 1713-1720 Nº de citas: 97 [doi:10.1200/JCO.18.01977]

Ciruelos E; Alba E; López R; Lluch A; Martín M; Arroyo I; Navarro B; Carcedo D; Colomer R; Albanell J.

Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval.

Oncotarget. 2019; 10(42): 4321-4332 [doi:10.18632/oncotarget.27039]

Gonzalez, R; Urbano, J; Solana, MJ; Hervias, M; Pita, A; Perez, R; Alvarez, R; Teigell, E; Gil-Jaurena, JM; Zamorano, J; Sobrino, A; Lopez-Herce, J.

Microcirculatory Differences in Children With Congenital Heart Disease According to Cyanosis and Age

Frontiers In Pediatrics. 2019; 7: Nº de citas: 7 [doi:10.3389/fped.2019.00264]

Conteduca, V; Castro, E; Wetterskog, D; Scarpi, E; Jayaram, A; Romero-Laorden, N; Olmos, D; Gurioli, G; Lolli, C; Sacz, MI; Puente, J; Schepisi, G; Salvi, S; Wingate, A; Medina, A; Querol-Ninerola, R; Marin-Aguilera, M; Arranz, JA; Fornarini, G; Basso, U; Mellado, B; Gonzalez-Billalabeitia, E; Attard, G; De Giorgi, U.

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

EUROPEAN JOURNAL OF CANCER. 2019; 116: 158-168 Nº de citas: 27 [doi:10.1016/j.ejca.2019.05.007]

Sestak, I; Martin, M; Dubsky, P; Kronenwett, R; Rojo, F; Cuzick, J; Filipits, M; Ruiz, A; Gradishar, W; Soliman, H; Schwartzberg, L; Buus, R; Hlauschek, D; Rodriguez-Lescure, A; Gnant, M.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

BREAST CANCER RESEARCH AND TREATMENT. 2019; 176(2): 377-386 Nº de citas: 71 [doi:10.1007/s10549-019-05226-8]

Carrato, A; Benavides, M; Massuti, B; Ferreiro-Monteagudo, R; Alfonso, PG; Falco, E; Reboredo, M; Cano, T; Gallego, J; Vieitez, JM; Layos, L; Salud, A; Polo, E; Dotor, E; Duran-Ogalla, G; Rodriguez-Garrote, M; Calvo, A; Grande, E; Aranda, E.

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

BMC CANCER. 2019; 19: Nº de citas: 13 [doi:10.1186/s12885-019-5753-7]

Picornell, AC; Echavarria, I; Alvarez, E; Lopez-Tarruella, S; Jerez, Y; Hoadley, K; Parker, JS; del Monte-Millan, M; Ramos-Medina, R; Gayarre, J; Ocana, I; Cebollero, M; Massarrah, T; Moreno, F; Saenz, JAG; Moreno, HG; Ballesteros, A; Borrego, MR; Perou, CM; Martin, M.

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

BMC GENOMICS. 2019; 20: Nº de citas: 40 [doi:10.1186/s12864-019-5849-0]

Cortes, J; Andre, F; Goncalves, A; Kummel, S; Martin, M; Schmid, P; Schuetz, F; Swain, SM; Easton, V; Pollex, E; Deurloo, R; Dent, R.

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

Future Oncology. 2019; 15(17): 1951-1961 Nº de citas: 64 [doi:10.2217/fon-2019-0059]

Domine, M; Massuti, B; Puente, J; Calles, A; Esteban, E; Triguboff, E; Afonzo, YS; Girones, R; Aparisi, F; Oramas, J.

Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease

ADVANCES IN THERAPY. 2019; 36(6): 1497-1508 Nº de citas: 4 [doi:10.1007/s12325-019-00931-8]

Rivera, F; Romero, C; Jimenez-Fonseca, P; Izquierdo-Manuel, M; Salud, A; Martinez, E; Jorge, M; Arrazubi, V; Mendez, JC; Garcia-Alfonso, P; Reboredo, M; Barriuso, J; Munoz-Unceta, N; Jimeno, R; Lopez, C.

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2019; 83(6): 1175-1181 Nº de citas: 49 [doi:10.1007/s00280-019-03820-7]